24 November 2020 - Late treatment study
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
et al., NEJM, doi:0.1056/NEJMoa2031304 (Peer Reviewed)
RCT 333 hospitalized patients in Argentina, 228 treated with convalescent plasma, showing no significant differences in clinical status or mortality. NCT04383535.
|
risk of death, 4.1% lower, RR 0.96, p = 1.00, treatment 25 of 228 (11.0%), control 12 of 105 (11.4%), NNT 216.
|
|
risk of 7-point scale, 19.0% lower, RR 0.81, p = 0.40, treatment 228, control 105, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Simonovich et al., 11/24/2020, Randomized Controlled Trial, Argentina, South America, peer-reviewed, 39 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.